2 weeks Ago
Ginkgo Bioworks Holdings, Inc. ( NYSE: DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matt Sykes - Goldman Sachs John Kim - Bank of America Mark Massaro - BTIG Jacquie Kesa - TD Cowen Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks.
I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks, as always for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties. Today, in addition to updating you on the quarter, we are going to provide updates on our path towards adjusted EBITDA breakeven as well as customer progress in our cell engineering business and our latest H5N1 offerings.
As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via X at #GinkgoResults or e-mail investors at ginkgobio.com.
All right. Over to you, Jason. Jason Kelly Thanks, Megan, and thanks, everyone, for joining us.
We always start with our mission of making biology easier to engineer here at Ginkgo and similar to last quarter, we continue to focus on three key objectives. First, we want to reach adjusted EBITDA breakeven while maintaining a cash margin of safety. And we ended this quarter with $616 million in cash and no bank debt and have already exceeded our cost-cutting target for 2024.
In other words, we've hit the target we're trying to hit.
